SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-3/A - Registration statement by foreign private issuers: [Amend]
SEC Accession No. 0001104659-20-046475
Filing Date
2020-04-15
Accepted
2020-04-14 18:20:33
Documents
8

Document Format Files

Seq Description Document Type Size
1 F-3/A tm2015499d1_f3a.htm F-3/A 607901
2 EXHIBIT 5.1 tm2015499d1_ex5-1.htm EX-5.1 38817
3 EXHIBIT 23.1 tm2015499d1_ex23-1.htm EX-23.1 6064
4 GRAPHIC tm2013443d1_f3sp1-img001.jpg GRAPHIC 14892
5 GRAPHIC tm2013443d1_f3sp1-img002.jpg GRAPHIC 13402
6 GRAPHIC mwe-logo.jpg GRAPHIC 3368
7 GRAPHIC mwe-footer.jpg GRAPHIC 3294
8 GRAPHIC mwe-sig.jpg GRAPHIC 2718
  Complete submission text file 0001104659-20-046475.txt   706578
Mailing Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018
Business Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: F-3/A | Act: 33 | File No.: 333-237389 | Film No.: 20792251
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences